tiprankstipranks
Prestige Consumer Healthcare (DE:PBV)
NYSE:PBV

Prestige Consumer Healthcare (PBV) Price & Analysis

0 Followers

PBV Stock Chart & Stats

€47.60
-€0.50(-0.70%)
At close: 4:00 PM EST
€47.60
-€0.50(-0.70%)

Bulls Say, Bears Say

Bulls Say
Free Cash Flow GenerationConsistent, high free cash flow (~$230M–$260M historically) provides durable internal funding for M&A, buybacks, and debt paydown. Strong FCF conversion supports financial flexibility and reduces reliance on external financing, sustaining strategic options over the next 2–6 months.
Improving Balance Sheet / DeleveragingMaterial reductions in leverage and equity growth strengthen solvency and covenant headroom, enabling integration of acquisitions and capital returns. The step-change deleveraging increases resilience to shocks, though the drivers of the 2026 drop should be monitored for sustainability.
Margin Resilience And Low CapexStable mid-50s gross margins and low capital intensity underpin persistent high operating cash conversion and profitability. Low ongoing capex needs allow the company to sustain brand investment, marketing, and shareholder returns without eroding operating margins over the medium term.
Bears Say
Top-line WeaknessRecurrent flat-to-declining revenue trends limit the firm's ability to grow operating profit organically. With muted organic growth and a 2026 decline, sustaining margins and FCF growth will depend more on M&A and pricing, increasing execution dependency over the next several quarters.
Operational / Supply RiskProduction shutdowns and extended ramp timelines create persistent execution risk that can depress near-term sales and disturb retailer relationships. Repeated supply issues raise the chance of ongoing volatility in shipment timing and inventory, pressuring revenue for months while capacity normalizes.
Higher Near-term Leverage From AcquisitionsLarge, debt-funded deals increase secured borrowing and covenant reliance, raising leverage and refinancing risk in the near term. Even if accretive long term, the heavier debt load heightens sensitivity to integration execution and cash flow variability over the next 2–6 months.

Prestige Consumer Healthcare News

PBV FAQ

What was Prestige Consumer Healthcare’s price range in the past 12 months?
Prestige Consumer Healthcare lowest stock price was €38.00 and its highest was €67.00 in the past 12 months.
    What is Prestige Consumer Healthcare’s market cap?
    Prestige Consumer Healthcare’s market cap is €2.03B.
      When is Prestige Consumer Healthcare’s upcoming earnings report date?
      Prestige Consumer Healthcare’s upcoming earnings report date is Jul 30, 2026 which is in 21 days.
        How were Prestige Consumer Healthcare’s earnings last quarter?
        Prestige Consumer Healthcare released its earnings results on May 13, 2026. The company reported €1.078 earnings per share for the quarter, missing the consensus estimate of €1.219 by -€0.14.
          Is Prestige Consumer Healthcare overvalued?
          According to Wall Street analysts Prestige Consumer Healthcare’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Prestige Consumer Healthcare pay dividends?
            Prestige Consumer Healthcare does not currently pay dividends.
            What is Prestige Consumer Healthcare’s EPS estimate?
            Prestige Consumer Healthcare’s EPS estimate is 0.77.
              How many shares outstanding does Prestige Consumer Healthcare have?
              Prestige Consumer Healthcare has 47,372,166 shares outstanding.
                What happened to Prestige Consumer Healthcare’s price movement after its last earnings report?
                Prestige Consumer Healthcare reported an EPS of €1.078 in its last earnings report, missing expectations of €1.219. Following the earnings report the stock price went up 1.905%.
                  Which hedge fund is a major shareholder of Prestige Consumer Healthcare?
                  Currently, no hedge funds are holding shares in DE:PBV
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Prestige Consumer Healthcare

                    Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.

                    Prestige Consumer Healthcare (PBV) Earnings & Revenues

                    PBV Company Deck

                    PBV Earnings Call

                    Q4 2026
                    0:00 / 0:00
                    Earnings Call Sentiment|Neutral
                    Balanced: the call highlighted strong cash generation, margin resilience, strategic M&A (Pillar5, Breathe Right, LaCorium) and digital/channel strengths (e‑commerce ~18%), which position the company for medium‑term upside. However, significant near‑term execution risks—chiefly Clear Eyes supply disruptions, production ramp uncertainty, and shipping disruptions from geopolitical events—drove fiscal '26 revenue declines and create short‑term volatility. Management provided cautious fiscal '27 guidance that assumes improvement in the back half of the year and emphasized deleveraging after acquisitions.View all DE:PBV earnings summaries

                    PBV Stock 12 Month Forecast

                    Average Price Target

                    €62.99
                    ▲(32.34% Upside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"38":"€38","53":"€53","68":"€68","45.5":"€45.5","60.5":"€60.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":62.99493696,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€62.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":62.99493696,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€62.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":62.99493696,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€62.99</span>\n  </div></div>","useHTML":true}}],"tickPositions":[38,45.5,53,60.5,68],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.6,42.32268745846154,44.04537491692308,45.768062375384616,47.49074983384615,49.21343729230769,50.93612475076923,52.65881220923077,54.38149966769231,56.104187126153846,57.82687458461538,59.54956204307692,61.27224950153846,{"y":62.99493696,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.6,42.32268745846154,44.04537491692308,45.768062375384616,47.49074983384615,49.21343729230769,50.93612475076923,52.65881220923077,54.38149966769231,56.104187126153846,57.82687458461538,59.54956204307692,61.27224950153846,{"y":62.99493696,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.6,42.32268745846154,44.04537491692308,45.768062375384616,47.49074983384615,49.21343729230769,50.93612475076923,52.65881220923077,54.38149966769231,56.104187126153846,57.82687458461538,59.54956204307692,61.27224950153846,{"y":62.99493696,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":67.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.6,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Cardinal Health
                    Henry Schein
                    McKesson
                    Guardian Pharmacy Services, Inc. Class A

                    Options Prices

                    Currently, No data available
                    ---
                    Popular Stocks